Immune Safety Avatar
Nonclinical mimicking of the immune system effects of immunomodulatory therapies
The imSAVAR Vision
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy.
The imSAVAR is an Innovative Medicines Initiative funded project that aims to develop a standard for integrated nonclinical safety overviews for immune-modulatory investigational new drugs (IND) and clinical trial applications (CTA).
Our imSAVAR platform will improve the prediction of the transferability of safety and efficacy of immunomodulators from pre-clinical models to first-in-human studies in collaboration with the private sector, pharma, regulators and technology providers. This joint effort not only benefits the field of immune safety evaluation, but will also generate various opportunities for European businesses as well as foster the meaningful engagement of multiple stakeholders including patients and regulators.
Upcoming Events
“If we really want to move forward with these modern immunomodulatory therapies we need much more research on predictive markers and predictive models. With the imSAVAR project we aim to tackle the challenge of a better understanding of the complexity of the human immune system.”
Ulrike Köhl / Coordinator
“The imSAVAR team plans to characterise a range of innovative human-relevant models and biomarkers to enhance translational safety assessment of immunomodulatory therapeutics and ultimately lead to the development of safer efficacious medicines for patients.”
Jonathan Moggs / Coordinator
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Forum
Engage in lively discussions and help built up a strong imSAVAR stakeholder community.
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Latest News
PhD Portrait #2: Tengku Ibrahim Maulana
Many enthusiastic PhD candidates are working on imSAVAR. With their research, they contribute to the success of the project. We are happy to feature a second portrait of PhD
Integrating Patient Preferences in Nonclinical Assessment of Immunomodulatory Therapies – Shifting the Paradigm
Immune-related adverse events (irAEs) are one of the leading causes affecting success rates of immunomodulatory drugs requiring a concerted multistakeholder effort across the drug development process—especially within the nonclinical
PhD Portrait #1: Charline Sommer
Many enthusiastic PhD candidates are working on imSAVAR. With their research, they contribute to the success of the project. We are happy to feature a first portrait of PhD